HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
25 sources retrieved · Most recent: April 2026 · Index updated 15 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
THRAP3
thyroid hormone receptor associated protein 3
Chromosome 1 · 1p34.3
NCBI Gene: 9967Ensembl: ENSG00000054118.16HGNC: HGNC:22964UniProt: Q9Y2W1
277PubMed Papers
20Diseases
0Drugs
0Pathogenic Variants
FUNCTIONAL ROLE
Highly ConstrainedReceptorTranscription Factor
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
positive regulation of transcription by RNA polymerase IIexon-exon junction complexnucleusnucleoplasminjuryacute myeloid leukemiafacial painAbnormality of the skeletal system
✦AI Summary

THRAP3 is a multifunctional transcriptional coregulator and RNA-binding protein with roles in splicing, transcriptional regulation, and cellular stress responses. Primary Function: THRAP3 functions in pre-mRNA splicing and remains associated with spliced mRNA through exon junction complex interactions 1. It regulates alternative splicing of specific genes including PTPRC/CD45 and controls mRNA stability of CCND1 1. THRAP3 acts as a coactivator of circadian clock regulation through the CLOCK-BMAL1 heterodimer and modulates PPARγ-dependent transcription in adipocytes 12. Mechanism: THRAP3 interacts with phosphorylated PPARγ at Ser273 to control diabetic gene programming 2. It suppresses AMPK-mediated autophagy in hepatocytes by direct binding and nuclear-cytoplasmic translocation regulation 3. THRAP3 promotes R-loop resolution via DDX5 interaction and methylation-dependent recruitment of XRN2 4. In AML, THRAP3 recruits SLU7 to facilitate GIT2 alternative splicing, promoting ferroptosis resistance 5. Disease Relevance: THRAP3 mutations occur in parathyroid carcinoma 6. THRAP3 is significantly overexpressed in blood cancers (DLBCL, BL, AML) and associated with poor prognosis and chemotherapy resistance 78. High THRAP3 expression correlates with poor AML prognosis and ferroptosis resistance 5. In BRAF-mutated colorectal cancer, nuclear PD-L1 inhibits THRAP3 to promote cell cycle progression 9. Clinical Significance: THRAP3 represents a potential therapeutic target in multiple cancers, type 2 diabetes, and NAFLD, with metformin-mediated THRAP3 suppression shown to inhibit MM cell proliferation 8.

Sources cited
1
Primary Function: THRAP3 functions in pre-mRNA splicing and remains associated with spliced mRNA through exon junction complex interactions .
PMID: 24043798
2
THRAP3 acts as a coactivator of circadian clock regulation through the CLOCK-BMAL1 heterodimer and modulates PPARγ-dependent transcription in adipocytes , .
PMID: 25316675
3
It suppresses AMPK-mediated autophagy in hepatocytes by direct binding and nuclear-cytoplasmic translocation regulation .
PMID: 37524868
4
THRAP3 promotes R-loop resolution via DDX5 interaction and methylation-dependent recruitment of XRN2 .
PMID: 34697388
5
In AML, THRAP3 recruits SLU7 to facilitate GIT2 alternative splicing, promoting ferroptosis resistance .
PMID: 41326370
6
Disease Relevance: THRAP3 mutations occur in parathyroid carcinoma .
PMID: 30641523
7
In BRAF-mutated colorectal cancer, nuclear PD-L1 inhibits THRAP3 to promote cell cycle progression .
PMID: 34923044
8
THRAP3 is significantly overexpressed in blood cancers (DLBCL, BL, AML) and associated with poor prognosis and chemotherapy resistance , .
PMID: 36762777
Disease Associationsⓘ20
injuryOpen Targets
0.26Weak
acute myeloid leukemiaOpen Targets
0.24Weak
facial painOpen Targets
0.24Weak
Abnormality of the skeletal systemOpen Targets
0.22Weak
lung adenocarcinomaOpen Targets
0.19Weak
urinary bladder carcinomaOpen Targets
0.19Weak
chronic lymphocytic leukemiaOpen Targets
0.19Weak
hepatocellular carcinomaOpen Targets
0.19Weak
gliomaOpen Targets
0.19Weak
melanomaOpen Targets
0.19Weak
papillary thyroid carcinomaOpen Targets
0.19Weak
colon adenocarcinomaOpen Targets
0.19Weak
esophageal squamous cell carcinomaOpen Targets
0.19Weak
head and neck squamous cell carcinomaOpen Targets
0.19Weak
cutaneous melanomaOpen Targets
0.19Weak
squamous cell lung carcinomaOpen Targets
0.19Weak
multiple myelomaOpen Targets
0.19Weak
HER2 Positive Breast CarcinomaOpen Targets
0.18Weak
lung carcinomaOpen Targets
0.18Weak
skin basal cell carcinomaOpen Targets
0.18Weak
Pathogenic Variants
No pathogenic variants reported on ClinVar for this gene.
View on ClinVar ↗
Related Genes
CBLL1Protein interaction100%MED11Protein interaction100%MED18Protein interaction100%MED17Protein interaction100%MED4Protein interaction100%MED30Protein interaction100%
Tissue Expression6 tissues
Brain
100%
Heart
97%
Lung
79%
Liver
70%
Ovary
68%
Bone Marrow
52%
Gene Interaction Network
Click a node to explore
THRAP3CBLL1MED11MED18MED17MED4MED30
PROTEIN STRUCTURE
Preparing viewer…
AlphaFoldAI-predicted · UniProt Q9Y2W1
View on AlphaFold ↗
Constraintⓘ
LOEUFⓘ
0.24Highly Constrained
pLIⓘ
1.00Intolerant
Observed/Expected LoF0.16 [0.11–0.24]
RankingsWhere THRAP3 stands among ~20K protein-coding genes
  • #1,315of 20,598
    Most Researched277 · top 10%
  • #727of 17,882
    Most Constrained (LOEUF)0.24 · top 5%
Genes detectedTHRAP3
Sources retrieved25 papers
Response time—
📄 Sources
25▼
1
Parathyroid Carcinoma.
PMID: 30641523
Front Horm Res · 2019
1.00
2
Biological roles of THRAP3, STMN1 and GNA13 in human blood cancer cells.
PMID: 39345963
3 Biotech · 2024
0.90
3
Metformin attenuates multiple myeloma cell proliferation and encourages apoptosis by suppressing METTL3-mediated m6A methylation of THRAP3, RBM25, and USP4.
PMID: 36762777
Cell Cycle · 2023
0.80
4
THRAP3 promotes ferroptosis resistance in acute myelocytic leukemia through SLU7-mediated alternative splicing of GIT2.
PMID: 41326370
Nat Commun · 2025
0.70
5
The RNA processing factors THRAP3 and BCLAF1 promote the DNA damage response through selective mRNA splicing and nuclear export.
PMID: 29112714
Nucleic Acids Res · 2017
0.60